AU2001271824A1 - Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes - Google Patents
Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymesInfo
- Publication number
- AU2001271824A1 AU2001271824A1 AU2001271824A AU7182401A AU2001271824A1 AU 2001271824 A1 AU2001271824 A1 AU 2001271824A1 AU 2001271824 A AU2001271824 A AU 2001271824A AU 7182401 A AU7182401 A AU 7182401A AU 2001271824 A1 AU2001271824 A1 AU 2001271824A1
- Authority
- AU
- Australia
- Prior art keywords
- glutathione
- prevention
- phase
- treatment
- neurodegenerative diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 108010024636 Glutathione Proteins 0.000 title 1
- 238000001784 detoxification Methods 0.000 title 1
- 229960003180 glutathione Drugs 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21581200P | 2000-07-05 | 2000-07-05 | |
US60/215,812 | 2000-07-05 | ||
PCT/US2001/021225 WO2002002190A2 (en) | 2000-07-05 | 2001-07-05 | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001271824A1 true AU2001271824A1 (en) | 2002-01-14 |
Family
ID=22804500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001271824A Abandoned AU2001271824A1 (en) | 2000-07-05 | 2001-07-05 | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
Country Status (3)
Country | Link |
---|---|
US (1) | US6812248B2 (en) |
AU (1) | AU2001271824A1 (en) |
WO (1) | WO2002002190A2 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19853487A1 (en) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Use of dialkyl fumarate for treating transplant rejection and autoimmune disease |
DE10000577A1 (en) * | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Treating mitochondrial diseases, e.g. Parkinson's or Alzheimer's disease or retinitis pigmentosa, using fumaric acid derivative, e.g. mono- or dialkyl fumarate, having succinate dehydrogenase stimulating activity |
WO2002038141A2 (en) * | 2000-11-08 | 2002-05-16 | Massachusetts Institute Of Technology | Compositions and methods for treatment of mild cognitive impairment |
WO2002087593A1 (en) * | 2001-04-25 | 2002-11-07 | Cobalz Limited | A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method |
AU2002333018B2 (en) * | 2001-09-27 | 2006-08-31 | The Mental Health Research Institute Of Victoria | Modulation of physiological processes and agents useful for same |
US7199122B2 (en) * | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
JP2007530417A (en) * | 2003-07-01 | 2007-11-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Composition for manipulating the longevity and stress response of cells and organisms |
AU2004269903B2 (en) * | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
MXPA06006980A (en) * | 2003-12-22 | 2006-12-14 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy. |
ZA200605378B (en) * | 2003-12-22 | 2008-01-30 | Alcon Inc | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
JP2007527418A (en) | 2003-12-29 | 2007-09-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Composition for treating or preventing obesity and insulin resistance disorders |
EP1577320B1 (en) | 2004-03-19 | 2012-07-18 | Institut Pasteur | Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides |
US20080096238A1 (en) * | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
US20060115870A1 (en) * | 2004-03-30 | 2006-06-01 | Alcon, Inc. | High throughput assay for human Rho kinase activity |
US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
US20060084085A1 (en) * | 2004-06-16 | 2006-04-20 | Sinclair David A | Methods and compositions for modulating Bax-mediated apoptosis |
US20070244202A1 (en) * | 2004-06-28 | 2007-10-18 | Kao Corporation | Ampk Activator |
WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
US20140099364A2 (en) | 2004-10-08 | 2014-04-10 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
US20060116423A1 (en) * | 2004-10-18 | 2006-06-01 | Dash Pramod K | Methods and compositions for treatment of central nervous system injury with isothiocyanates |
US7402726B2 (en) | 2004-11-09 | 2008-07-22 | The University Of Washington | Methods and compositions for screening for modulators of Parkinson's disease |
US20060174356A1 (en) * | 2004-11-09 | 2006-08-03 | Pallanck Leo J | Methods and compositions for screening for modulators of neuronal cell death in Parkinson's disease |
AU2006204699B2 (en) * | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
US7744937B2 (en) * | 2005-08-09 | 2010-06-29 | Kraft Foods Global Brands Llc | Chemoprotectants from crucifer seeds and sprouts |
CA2666461A1 (en) * | 2006-10-10 | 2008-09-12 | Burnham Institute For Medical Research | Neuroprotective compositions and methods |
HUE046151T2 (en) * | 2007-01-23 | 2020-02-28 | Pharmagra Labs Inc | Stabilized sulforaphane |
US20100130607A1 (en) * | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
ES2916649T3 (en) | 2007-02-08 | 2022-09-21 | Biogen Ma Inc | Compositions and uses for the treatment of multiple sclerosis |
US20080311276A1 (en) * | 2007-06-12 | 2008-12-18 | Kraft Foods Holdings, Inc. | Production of Glucosinolates from Agricultural By-Products & Waste |
US20080311192A1 (en) * | 2007-06-12 | 2008-12-18 | Kraft Foods Holdings, Inc. | Enteric-Coated Glucosinolates And Beta-Thioglucosidases |
JP2010539102A (en) * | 2007-09-11 | 2010-12-16 | ジョスリン ダイアベティス センター インコーポレイテッド | Phase II detoxification and antioxidant activity |
GB0811992D0 (en) * | 2008-07-01 | 2008-08-06 | Mithen Richard | Treatment |
KR101192699B1 (en) * | 2008-11-19 | 2012-10-19 | 국립암센터 | A pharmaceutical composition for preventing or treating transglutaminase-related disease comprising oltipraz, and a method for preventing or treating transglutaminase-related disease by using thereof |
PT2379063E (en) | 2009-01-09 | 2013-05-03 | Forward Pharma As | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
GB201101793D0 (en) * | 2011-02-02 | 2011-03-16 | Univ Edinburgh | Weight related disorders |
EP2678029B1 (en) | 2011-02-22 | 2016-11-09 | Caudill Seed Company, Inc. | Spray dried myrosinase and use to produce isothiocyanates |
EP2709612A4 (en) * | 2011-05-19 | 2015-07-01 | Glax L L C | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells |
ITMI20121774A1 (en) * | 2012-10-19 | 2014-04-20 | Placido Bramanti | USE OF A BIOACTIVATED PHYTOCHIMIC AS A NEUROPROTECTIVE AGENT FOR THE PREVENTION AND TREATMENT OF PATHOLOGIES RELATED TO THE NERVOUS SYSTEM |
JP6944690B2 (en) * | 2017-02-21 | 2021-10-06 | 株式会社アミンファーマ研究所 | Glutathione-S-transferase (GST) expression enhancer |
CN112236145A (en) * | 2018-03-07 | 2021-01-15 | Ama生物制药公司 | Compounds for the treatment of alzheimer's disease |
WO2020097320A1 (en) * | 2018-11-08 | 2020-05-14 | Neurolign Usa, Llc | Rehabilitation of subjects with pharmacologically induced neuroplasticity |
CA3158912A1 (en) * | 2019-11-18 | 2021-05-27 | Societe Des Produits Nestle S.A. | Compositions and methods for glutathione enhancement for use in brain health |
WO2022047212A1 (en) * | 2020-08-27 | 2022-03-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating neurodegenerative disorders |
US11813313B2 (en) | 2021-02-25 | 2023-11-14 | Gateway Institute for Brain Research, LLC | Method of treating Parkinson's disease with intranasal delivery of insulin and glutathione |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411986A (en) | 1993-03-12 | 1995-05-02 | The Johns Hopkins University | Chemoprotective isothiocyanates |
US5780489A (en) | 1996-08-21 | 1998-07-14 | Brooks; Benjamin Rix | Method for treating amyotrophic lateral sclerosis |
US6184248B1 (en) * | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
-
2001
- 2001-07-05 WO PCT/US2001/021225 patent/WO2002002190A2/en active Application Filing
- 2001-07-05 AU AU2001271824A patent/AU2001271824A1/en not_active Abandoned
- 2001-07-05 US US09/897,934 patent/US6812248B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002002190A3 (en) | 2003-08-28 |
US6812248B2 (en) | 2004-11-02 |
US20020091087A1 (en) | 2002-07-11 |
WO2002002190A2 (en) | 2002-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001271824A1 (en) | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes | |
AU2003290548A1 (en) | Prevention and treatment of synucleinopathic disease | |
AU2002332430A1 (en) | Methods of treating neuropilin-mediated diseases | |
AU2002240453A1 (en) | Wastewater treatment system and method of control | |
AU2001239052A1 (en) | Compositions for prevention and treatment of dementia | |
AU2003225281A1 (en) | Materials and methods for prevention and treatment of rna viral diseases | |
AU2001286983A1 (en) | Method of treatment | |
AUPQ515000A0 (en) | Treatment of uv induced immunosuppression | |
AU2002231206A1 (en) | Treatment of depression | |
AU4215499A (en) | Treatment of neurodegenerative diseases | |
AU2003213898A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
AU1261601A (en) | Treatment of C. difficile toxin B associated conditions | |
AU2000275035A1 (en) | Therapeutic and prophylactic drugs of myopia | |
AU2001267165A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
AU2001262741A1 (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
AU2001262177A1 (en) | Method of treatment | |
AU1405001A (en) | Treatment of diseases | |
AU2003264954A1 (en) | Pharmaceutical composition for prevention and treatment of kidney diseases | |
AU4034800A (en) | Novel compositions and methods for prevention and treatment of protozoal disease | |
AU3735900A (en) | Methods of treatment and prevention of restenosis | |
AU2001281465A1 (en) | Treatment of rosacea | |
AU2001253560A1 (en) | Methods of treatment | |
AU2001274080A1 (en) | Regulation of human transketolase-like enzyme | |
AU4598400A (en) | Method of treatment | |
AU1392601A (en) | Prevention and treatment of biomaterial-associated infections |